Goat Anti-Mouse IgG Fab-AP

Cat. No.
1015-04  
Size
1.0 mL  
Price (USD)
$135.00 
Specificity Reacts with the Fab region of mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3
Source Pooled antisera from goat hyperimmunized with mouse IgG
Cross Adsorption Mouse IgG Fc; may react with immunoglobulins from other species and the light chains of other mouse immunoglobulins
Purification Affinity chromatography on mouse IgG Fab covalently linked to agarose
Isotype Goat IgG
Format/Conjugate AP (Alkaline Phosphatase)
Buffer Formulation Supplied in a stock solution of 50 mM Tris/1 mM MgCl2/50% glycerol, pH 8.0, containing NaN3 as a preservative
Volume 1.0 mL
Storage & Handling Store at 2-8°C
Please refer to product specific SDS
Applications
Quality tested applications for relevant formats include -
ELISA 1-4
FLISA
Recommended Dilutions Please refer to product specific Technical Bulletin
  • ELISA plate was coated with purified mouse IgG Fab and IgG Fc. Immunoglobulins were detected with serially diluted Goat Anti-Mouse IgG Fab-AP (SB Cat. No. 1015-04).

ELISA plate was coated with purified mouse IgG Fab and IgG Fc. Immunoglobulins were detected with serially diluted Goat Anti-Mouse IgG Fab-AP (SB Cat. No. 1015-04).
 
References
1. Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33:5578-87. (ELISA)
2. Alving CR, Beck Z, inventors; The Government of the United states of America as Represented by the Secretary of the Army, assignee. Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin. United States patent application publication US 2017/0182152 A1. 2017 Jun 29. (ELISA)
3. Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J Control Release. 2018;275:12-19. (ELISA)
4. Lee J, Park E, Min J, Sung S, Jang Y, Shin JS, et al. Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Res. 2018;46:1635-47. (ELISA)